Figures
- Fig. 1.—
Schematic diagram showing the sampling method of the European Community Respiratory Health Survey I (1990–1993). IgE: immunoglobulin E.
- Fig. 2.—
Schematic diagram showing the sampling method of the European Community Respiratory Health Survey (ECRHS) II (1999–2002). Follow-up was performed 8–10 yrs after the initial survey. IgE: immunoglobulin E; DNA: deoxyribonucleic acid.
Tables
- Table 1—
Number of eligible participants per centre in the European Community Respiratory Health Survey (ECRHS) II as defined by number of responders to stage 2 of ECRHS I
Country Centre Eligible participants from random sample Eligible participants from symptomatic sample Total eligible participants Iceland Reykjavik 564 84 648 Sweden Umea 552 156 708 Uppsala 622 201 823 Goteborg 682 184 866 Estonia Tartu 431 127 558 Norway Bergen* 835 0 835 UK Norwich 473 108 581 Ipswich 448 111 559 Germany Hamburg*,# 1252 0 1252 Erfurt* 731 0 731 The Netherlands Groningen*,¶ 380 0 380 Geleen* 415 0 415 Bergen-op-zoom*,¶ 452 0 452 Belgium Antwerp City 564 87 651 South Antwerp 558 76 634 Switzerland Basel 853 149 1002 France Paris* 652 0 652 Bordeaux*,# 544 0 544 Grenoble 473 49 522 Montpellier*,# 456 0 456 Spain Oviedo 357 167 524 Galdakao 486 106 592 Barcelona 393 123 516 Albacete 435 191 626 Huelva 271 132 403 Italy Verona 340 18 358 Pavia* 310 0 310 Turin 244 111 355 USA Portland# 723 116 839 Australia Melbourne# 669 207 876 Total 16165 2503 18668 -
*: centres who, due to limited resources, only studied a representative sample of responders to stage 1 and therefore have no “symptomatic sample”
-
#: non-European Union funded centres taking part at their own expense
-
¶: at the time of writing this paper it was unlikely that this centre would provide data for ECRHS II
-
